StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ – Free Report) in a research note issued to investors on Thursday. The firm issued a hold rating on the medical research company’s stock.
Enzo Biochem Price Performance
ENZ remained flat at $1.13 during trading on Thursday. The company had a trading volume of 39,237 shares, compared to its average volume of 97,033. The stock has a 50 day simple moving average of $1.13 and a 200 day simple moving average of $1.12. Enzo Biochem has a twelve month low of $0.99 and a twelve month high of $1.50.
Enzo Biochem Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 15th will be given a dividend of $0.10 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $0.40 annualized dividend and a yield of 35.40%.
Institutional Investors Weigh In On Enzo Biochem
About Enzo Biochem
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
Read More
- Five stocks we like better than Enzo Biochem
- How to Read Stock Charts for Beginners
- Dot Ai IPO: CEO Ed Nabrotzky Shares Vision for Logistics Future
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- Upcoming IPO Stock Lockup Period, Explained
- The Top 5 Performing S&P 500 Stocks YTD in 2024
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.